SLU-PP-915
SLU-PP-915 is a small-molecule pan-ERR agonist with mouse oral activity, an 18-to-28-minute mouse oral half-life, and no human administration data.
tier C · 18-28 min mouse oral half-life range
verdict
The 2026 mouse paper establishes oral activity and short mouse exposure. It does not close the human evidence gap, and earlier fat-loss results still belong to SLU-PP-332.
what changed from 332: 915 is chemically distinct and orally active in mice. The 2026 study measured oral regimens at 2, 8, and 32 mg/kg.
what its mouse exposure looks like: The paper reports an 18-to-28-minute oral half-life and no accumulation after 14 doses in mice.
whether 915 has human data: No human administration study was located. Human liver microsome and S9 experiments are in vitro, not human pharmacokinetics or safety.
The direct 2026 evidence is mouse oral and intraperitoneal work. It does not create a human regimen.
why C-tier
C-tier reflects direct mouse oral and injected findings with no human administration evidence.
the core tension
915 now has a specific oral mouse PK and efficacy record. The entire in-vivo record is still preclinical.
what it is
SLU-PP-915, called compound 10s in the discovery paper, is a boronic-acid thiophene small molecule and pan-agonist of ERR alpha, beta, and gamma. It was developed as an orally active successor to SLU-PP-332.
what it does
In mice, 915 changed exercise-response and mitochondrial gene programs and increased exercise capacity after intraperitoneal and oral administration. The 2026 paper tested oral 2, 8, and 32 mg/kg and compared a 32 mg/kg oral multiple-dose arm with 20 mg/kg intraperitoneally twice daily for 7 days.
origin
The Burris research group identified 915 in a medicinal-chemistry series and then published the dedicated oral mouse paper in the January 2026 issue of the Journal of Pharmacology and Experimental Therapeutics.
why researchers are interested
Oral activity solves a concrete problem in 332. The remaining gap is not delivery inside a mouse; it is the absence of human exposure, safety, and outcomes.
does it work
The dedicated paper reports mouse exercise effects after oral and intraperitoneal administration, an oral half-life of 18 to 28 minutes, and no accumulation after 14 doses. No human administration result was located. The earlier obesity and metabolic-syndrome paper tested 332, not 915.
key facts
- molecular formula: C17H13BFNO3S
- molecular weight: 341.19 g/mol
- amino acids: not a peptide
- half-life: 18 to 28 minutes after oral administration in mice; no human half-life
- type: boronic-acid thiophene small-molecule pan-ERR agonist
- CAS: 2285432-92-8
- 2/8/32 mg/kg mouse oral groups
- 18-28 min mouse oral half-life
- 14 mouse doses with no accumulation
- 0 human administration studies located
frequently asked questions
Is SLU-PP-915 a peptide?
No. It is a boronic-acid thiophene small molecule and pan-ERR agonist.
What did the 2026 study add?
It added exact mouse oral regimens, short mouse oral pharmacokinetics, multiple-dose exposure, and oral exercise-capacity results.
What was the mouse half-life?
The paper reports 18 to 28 minutes after oral administration in mice. No human half-life is known.
Does 915 have direct fat-loss evidence?
The well-known metabolic-syndrome and fat-mass paper tested 332, not 915. The 2026 paper discusses potential metabolic applications but does not turn the older 332 result into a 915 result.
related peptides
- SLU-PP-332: parent research program; source of the older metabolic-syndrome result
- 5-amino-1mq: different target and animal-only metabolic record
reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.
